DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
44.98
+0.03 (+0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close44.95
Open44.98
Bid43.03 x 400
Ask46.00 x 100
Day's Range43.90 - 45.21
52 Week Range42.62 - 88.80
Volume1,326,838
Avg. Volume2,004,272
Market Cap3.89B
Beta0.23
PE Ratio (TTM)-58.87
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer Remix: My mea culpa on DexCom and where it’s heade...
    CNBC Videos15 days ago

    Cramer Remix: My mea culpa on DexCom and where it’s heade...

    Jim Cramer analyzes the huge drop in DexCom and whether he thinks the stock could rebound.

  • Capital Cube3 days ago

    ETFs with exposure to DexCom, Inc. : October 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DexCom, Inc. Here are 5 ETFs with the largest exposure to DXCM-US. Comparing the performance and risk of DexCom, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Benzinga11 days ago

    DexCom's Quiet Consolidation After Huge Decline

    DexCom, Inc. (NASDAQ: DXCM ) shares got hammered Sept. 28 when rival Abbott Laboratories (NYSE: ABT ) received  FDA approval for its FreeStyle Libre flash glucose monitoring system. Investors see Abbott’s ...

  • Capital Cube14 days ago

    ETFs with exposure to DexCom, Inc. : October 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DexCom, Inc. Here are 5 ETFs with the largest exposure to DXCM-US. Comparing the performance and risk of DexCom, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
    Capital Cube15 days ago

    DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017

    Categories: Yahoo FinanceGet free summary analysis DexCom, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of DexCom, Inc. – MGC Diagnostics Corporation and Medtronic plc (MGCD-US and MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 170.60 million, Net Earnings ... Read more (Read more...)

  • 5 Top Stocks for October
    Motley Fool15 days ago

    5 Top Stocks for October

    Looking for a few great stocks to buy this month? Here are five top opportunities for you to consider.

  • Cramer Remix: My mea culpa on DexCom and where it’s headed
    CNBC16 days ago

    Cramer Remix: My mea culpa on DexCom and where it’s headed

    Jim Cramer analyzes the huge drop in DexCom and whether he thinks the stock could rebound.

  • Market Realist17 days ago

    How Wall Street Reacted to the FDA Approval of Abbott’s Freestyle Libre

    DXCM stock fell following ABT's announcement, while ABT’s stock price rose. The Vanguard Dividend Appreciation ETF (VIG) rose that day as well.

  • What Happened in the Stock Market Today
    Motley Fool22 days ago

    What Happened in the Stock Market Today

    Indexes advanced, but DexCom tumbled on a competitive threat and Rite Aid fell after reporting earnings.

  • Associated Press22 days ago

    DexCom and Rite Aid tumble while Abbott and AbbVie rise

    Stocks that moved substantially or traded heavily Thursday: Abbott Laboratories, up $1.49 to $53.64 Regulators approved Abbott's new blood glucose monitoring system. Hain Celestial Group Inc., up 28 cents ...

  • 24/7 Wall St.22 days ago

    Rite Aid, DexCom Plunge into Thursday’s 52-Week Low Club

    Rite Aid, DexCom, Uniti Group, and SCANA all posted new 52-week lows on Thursday.

  • The FDA just approved a device that can monitor blood sugar without finger pricks
    Business Insider22 days ago

    The FDA just approved a device that can monitor blood sugar without finger pricks

    The FDA on Wednesday approved a device that monitors blood sugar levels without needing to...

  • TheStreet.com22 days ago

    Buy Abbott Labs as It Obliterates DexCom Stock, Jim Cramer Says

    Shares of DexCom are down more than 35% Thursday after Abbott Labs secured FDA approval for its new glucose monitoring system. Jim Cramer calls Abbott Labs a buy.

  • Benzinga22 days ago

    Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition

    Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM )'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock with ...

  • Why DexCom Stock Is Getting Crushed Today
    Motley Fool22 days ago

    Why DexCom Stock Is Getting Crushed Today

    The maker of continuous glucose monitoring systems for diabetes management faces a new competitive threat.

  • CNBC22 days ago

    Abbott shares jump after approval for diabetes monitor; competitor DexCom crashes on surprise news

    The Food and Drug Administration approved Abbott's FreeStyle Libre glucose monitoring system.

  • Barrons.com22 days ago

    DexCom: Stay Sweet or Go Sour?

    Today, shares of DexCom (DXCM) has plunged 36% to just over $43 after Abbott Laboratories (ABT) received FDA approval for a blood sugar-monitoring system for diabetics that doesn't require a finger prick. Abbott plans to sell it at retail pharmacies, and pursue the all-important Medicare reimbursement As one might expect, Abbott’s stock price climbed 4.1% to $54.32 a share, given that it’s a big potential upside to the company’s diabetes care franchise. As Joanne Wuensch at BMO Capital Markets writes: On the commercial side we expect significant patient demand: For example, in Europe, which includes full reimbursement in France and in the U.K., and over 400,000 patients there use the Libre.

  • Investopedia22 days ago

    Fitbit Stock Briefly Touches New Highs

    Fitbit shares recently hit a new 52-week high but remain below this key trendline resistance level.

  • Reuters23 days ago

    FDA approves Abbott's blood glucose monitoring device

    The U.S. Food and Drug Administration said it approved Abbott Laboratories' glucose monitoring device for adults with diabetes, allowing millions of people to track their blood sugar levels without having to prick their fingers. Abbott's FreeStyle Libre Flash reduces the need for fingerstick testing, which is painful and inconvenient, by inserting a small sensor wire below the skin to continuously measure and monitor glucose levels. Chicago-based Abbott's shares were trading up 3.6 percent at $54 after the bell on Wednesday.

  • FDA Approves First Finger Prick-Free Device for Diabetics
    Bloomberg23 days ago

    FDA Approves First Finger Prick-Free Device for Diabetics

    For many American diabetics, finger pricks will soon be replaced by a wearable sensor the size of a bottle cap.

  • Reuters23 days ago

    FDA approves Abbott's blood glucose monitoring device

    The U.S. Food and Drug Administration on Wednesday approved Abbott Laboratories' glucose monitoring device for adults with diabetes, allowing millions of people to track their blood sugar levels without having to prick their fingers. Abbott's FreeStyle Libre Flash reduces the need for fingerstick testing, which is painful and inconvenient, by using a small sensor wire that is inserted below the skin to continuously measure and monitor glucose levels. Chicago-based Abbott's shares were trading up about 2 percent at $53.25 after the bell on Wednesday.

  • Fitbit Inc (FIT) Stock Looks Good for the Very Short Term
    InvestorPlace24 days ago

    Fitbit Inc (FIT) Stock Looks Good for the Very Short Term

    FIT stock also should benefit from year-over-year comparisons. According to various reviews, it appears that the device is having issues with its cellular features, such as connection with LTE networks as well as problems with the draining of the battery.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    Dexcom Inc NASDAQ/NGS:DXCM

  • Investopedialast month

    Fitbit Stock Tests Support After Breakout Fizzles

    FitBit shares moved lower amid concerns over smartwatch competition and profit taking from a recent rally.

  • Fitbit Inc (NYSE:FIT) Stock Still Has A Lot of Work To Do
    InvestorPlacelast month

    Fitbit Inc (NYSE:FIT) Stock Still Has A Lot of Work To Do

    Fitbit Inc (NYSE:FIT) stock has finally broken out. Fitbit stock traded mostly between $5 and $6 after plunging. InvestorPlace columnist Larry Ramer argued the product would give a boost to FIT stock, and he may be right.